Acurx Pharmaceuticals to Present at Microcap Conference in 2025

Acurx Pharmaceuticals, Inc., a biopharmaceutical firm specializing in antibiotics for challenging bacterial infections, announced its participation in the upcoming Microcap Conference. Scheduled from January 28-30, 2025, at the Borgata Hotel in Atlantic City, this event will feature a presentation by CEO David P. Luci on January 29 at 10 am ET.

Focused on antibiotic development, Acurx is advancing its lead candidate, ibezapolstat, which is Phase 3 ready for treating C. difficile infections. Their innovative approach targets Gram-positive bacteria, including challenging pathogens like MRSA and VRE. The firm is preparing for international clinical trials and expanding its preclinical pipeline for severe infections such as anthrax.